Literature DB >> 10229914

Identification of thyroid hormone residues on serum thyroglobulin: a clue to the source of circulating thyroglobulin in thyroid diseases.

L Druetta1, H Bornet, G Sassolas, B Rousset.   

Abstract

Thyroglobulin (Tg) present in the serum of normal individuals and patients with thyroid disorders could be partly newly synthesized non-iodinated Tg and partly Tg containing iodine and hormone residues originating from the lumen of thyroid follicles. With the aim of examining the contribution of the latter source of Tg to the elevation of serum Tg concentration in thyroid pathophysiological situations, we devised a procedure to identify thyroxine (T4) and tri-iodothyronine (T3) residues on Tg from unfractionated serum. A two-step method, basedon (i)adsorption of Tg on an immobilized anti-human Tg (hTg) monoclonal antibody (mAb) and (ii)recognition of hormone residues on adsorbed Tg by binding of radioiodinated anti-T4 mAb and anti-T3 mAb, was used to analyze serum Tg from patients with either Graves' disease (GD), subacute thyroiditis (ST) or metastatic differentiated thyroid cancer (DTC). Purified hTg preparations with different iodine and hormone contents were used as reference. Adsorption of purified Tg and serum Tg on immobilized anti-hTg mAb ranged between 85 and 90% over a wide concentration range. Labeled anti-T4 and anti-T3 mAbs bound to adsorbed purified Tg in amounts related to its iodine content. Tg adsorbed from six out of six sera from ST exhibited anti-T4 and anti-T3 mAb binding activities. In contrast, significant mAb binding was only observed in one out of eight sera from untreated GD patients and in 1 out of 13 sera from patients with DTC. The patient with DTC, whose serum Tg contained T4 and T3, represented a case of hyperthyroidism caused by a metastatic follicular carcinoma. In conclusion, we have identified, for the first time, T4 and T3 residues on circulating Tg. The presence of Tg with hormone residues in serum is occasional in GD and DTC but is a common and probably distinctive feature of ST.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10229914     DOI: 10.1530/eje.0.1400457

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  4 in total

1.  Failure to use measurement of megalin secretory components complexed with serum thyroglobulin as a tool to identify metastases after surgery in papillary thyroid cancer.

Authors:  S Lisi; F Menconi; M A Altea; L Agate; E Molinaro; M G Castagna; D Taddei; L Grasso; A Pinchera; R Elisei; M Marinò
Journal:  J Endocrinol Invest       Date:  2004 Jul-Aug       Impact factor: 4.256

2.  Preferential megalin-mediated transcytosis of low-hormonogenic thyroglobulin: a control mechanism for thyroid hormone release.

Authors:  Simonetta Lisi; Aldo Pinchera; Robert T McCluskey; Thomas E Willnow; Samuel Refetoff; Claudio Marcocci; Paolo Vitti; Francesca Menconi; Lucia Grasso; Fabiana Luchetti; A Bernard Collins; Michele Marino
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-01       Impact factor: 11.205

3.  Serum thyroglobulin is associated with orbitopathy in Graves' disease.

Authors:  S Khamisi; M Lundqvist; P Emadi; K Almby; Ö Ljunggren; F A Karlsson
Journal:  J Endocrinol Invest       Date:  2021-01-29       Impact factor: 4.256

4.  Molecular evidence reveals thyrotropin intervention enhances the risk of developing radioiodine-refractory differentiated thyroid carcinoma.

Authors:  Hilda Samimi; Vahid Haghpanah
Journal:  Cancer Cell Int       Date:  2022-02-03       Impact factor: 5.722

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.